BLAS LEDESMA: Open Payments
NPI 1457748345 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$904 in 26 payments from 13 companies in 2025. Trend: 2023 $207 · 2024 $327 · 2025 $904
Food & beverage: $805Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $296 |
| SEAGEN INC. | 1 | $99 |
| PFIZER INC. | 4 | $92 |
| Alexion Pharmaceuticals, Inc. | 3 | $92 |
| Kite Pharma, Inc. | 1 | $79 |
| Incyte Corporation | 2 | $50 |
| Adaptive Biotechnologies Corporation | 2 | $50 |
| SANOFI-AVENTIS U.S. LLC | 1 | $39 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $23 |
Products named: DARZALEX, RYBREVANT, ULTOMIRIS, Yescarta, clonoSEQ, BESPONSA, ELREXFIO, REZUROCK.
Industry payments across FL — which companies pay providers there.
